Early benefit of mepolizumab on small airways in severe asthma: insights from the IMPOSE study
This study is the first to demonstrate that mepolizumab has a rapid and sustained therapeutic effect on small airways in severe eosinophilic asthma, as shown by IOS. IOS proves to be a valuable tool for monitoring the effects of biologic treatments on small airway function, revealing insights beyond those provided by spirometry.
Authors
- Maria Pinaka
- Dimitra Siachpazidou (ORCID: https://orcid.org/0000-0002-7688-8072)
- Zoe Daniil (ORCID: https://orcid.org/0000-0002-1058-9125)
- Ourania S. Kotsiou (ORCID: https://orcid.org/0000-0001-5219-6971)
- Paraskevi Kirgou
- Konstantinos I. Gourgoulianis (ORCID: https://orcid.org/0000-0001-9541-1010)
- Κonstantinos Bartziokas (ORCID: https://orcid.org/0000-0002-9657-3705)
- Konstantinos Tourlakopoulos (ORCID: https://orcid.org/0000-0001-9155-7960)
- Foteini Malli (ORCID: https://orcid.org/0000-0002-7595-6715)
Institutions
- University of Thessaly (GR)
- e-Trikala (Greece) (GR)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1183/23120541.00939-2024
- Citations
- 7
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.29